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Ingestion of sodium is essential to health, but excess sodium intake is a risk factor for hypertension and cardiovascular disease. Defining an optimal
range of sodium intake in populations has been challenging and controversial. Clinical trials evaluating the effect of sodium reduction on blood
pressure have shown blood pressure lowering effects down to sodium intake of less than 1.5 g/day. Findings from these blood pressure trials form
the basis for current guideline recommendations to reduce sodium intake to less than 2.3 g/day. However, these clinical trials employed interven-
tions that are not feasible for population-wide implementation (i.e. feeding studies or intensive behavioural interventions), particularly in low and
middle-income countries. Prospective cohort studies have identified the optimal range of sodium intake to reside in the moderate range (3–5 g/
day), where the risk of cardiovascular disease and death is lowest. Therefore, there is consistent evidence from clinical trials and observational
studies to support reducing sodium intake to less than 5 g/day in populations, but inconsistent evidence for further reductions below a moderate
intake range (3–5 g/day). Unfortunately, there are no large randomized controlled trials comparing low sodium intake (< 3 g/day) to moderate so-
dium intake (3–5 g/day) in general populations to determine the net clinical effects of low sodium intake. Until such trials are completed, it is likely
that controversy about optimal sodium intake range will continue. This working group calls for the completion of large definitive clinical trials to
clarify the range of sodium intake for optimal cardiovascular health within the moderate to low intake range. We support interventions to reduce
sodium intake in populations who consume high sodium intake (> 5 g/day), which should be embedded within an overall healthy dietary pattern.
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The impressive reductions in cardiovascular disease (CVD) seen in
high-income countries over recent decades have not been seen in
low- and middle-income countries (LMICs), where both rates of
CVD and, given population growth and ageing, the total disease bur-
den are continuing to increase. The success in high-income countries
has been attributed to risk factor modification among most, although
not all of the population, especially reductions in smoking, treatment
of hypertension and hypercholesterolemia. Yet there are many bar-
riers to extending this success to LMICs, reflecting both limited cap-
acity to develop and implement healthy public policies in areas such
as diet and tobacco control and slow progress in extending coverage
with effective health care.
There is a renewed imperative to overcome these barriers following
the adoption of a United Nations High Level Declaration on Non-
Communicable Disease (NCD)1 and, more recently, the inclusion of a
target for reducing by one third premature mortality from NCDs
through prevention and treatment by 2030 in the Sustainable
Development Goals.2 Yet, if this ambitious target is to be achieved it will
require prioritization of those measures known to be both effective and
feasible in LMICs. Given its importance as a risk factor for CVD, such
measures must tackle the high global burden of hypertension, among
the leading modifiable risk factors for CVD in all parts of the world.3
While a comprehensive response must include expansion of detection
and treatment, attention has also focused on the role of sodium intake,
which has been shown to correlate positively with hypertension, albeit
with inter-individual variation in the strength of the association.4
Reducing sodium content, especially when embedded with a healthy
cardiovascular diet, exerts short-term reductions in blood pressure.
These considerations have led to the prominence of reducing sodium
intake as a strategy in CVD prevention guidelines.5,6 The WHO recom-
mends a 30% reduction in sodium intake worldwide by 2025, irrespect-
ive of the baseline mean sodium intake of a population, and
recommends a mean sodium intake target of <2 g/day.7 Public health ini-
tiatives to reduce excess sodium intake in populations have been
adopted by numerous countries, but predominantly in high-income
countries, with low impact so far in LMICs. However, while there is con-
sistent evidence that high sodium intake (> 5 g/day) is associated with
increased CV risk, there is little epidemiologic evidence linking an associ-
ation between moderate sodium intake and increased CV risk (com-
pared to low sodium intake recommended by WHO, < 2 g/day). There
is an ongoing scientific debate about the optimal lower level of sodium
intake for CVD prevention,8 but there is an acceptance that a lower limit
is present, since sodium is an essential nutrient. This implies that there
must be a ‘U’-shaped relationship between dietary sodium intake and
cardiovascular events, but there is no consensus of where the minimum
risk lies. To add to the complexity, a very recent analysis suggested that
sodium reduction might only benefit those persons with hypertension.9
There are other major barriers to developing effective interventions
for reducing sodium intake. First, the absence of accurate, feasible
methods to measure sodium intake in individuals results in current rec-
ommendations (e.g. < 2 g/day) that are difficult to interpret and imple-
ment in clinical practice. There is disagreement about the validity of
those relatively simple methods that are used for measuring mean in-
take in populations, such as spot urinary sodium measurement and, es-
pecially, their interpretation when used to assess individual risk.
Second, there are no randomized controlled trials (RCTs) that show
that reduction of sodium intake, from moderate to low levels, reduces
CVD. Third, while a number of interventions, both at individual such as
education, and population-level such as reformulation have been pro-
posed, they have so far not been shown empirically to result in sus-
tained reductions in sodium intake, particularly in LMICs. Fourth,
overall dietary pattern is an important determinant of health outcomes,
and recommendations based on sole nutrients need to consider the ef-
fect on overall dietary pattern, and regional variations in dietary pat-
terns (e.g. sources of sodium intake vary by region, and within regions).
The current statement does not seek to replicate prior guidelines
on sodium intake, but attempts to propose a practical approach to
sodium intake that can inform public policy and clinical practice in
adults in LMICs. We summarize knowledge-gaps in our understand-
ing of association between sodium intake and health, and recommend
future areas of research focus in LMICs.
Physiology of sodium
Sodium is an essential nutrient, required for numerous physiologic
processes. It is tightly regulated by numerous physiologic (renal, endo-
crine, immune) systems which act to maintain serum sodium within
normal range. Sodium exchange with potassium is a key part of the ac-
tion potential of human cells. In most people, normal kidneys are cap-
able of excreting large amounts of sodium, or excrete almost no
sodium, in settings of high and low sodium intake, respectively. Niche
populations with very low sodium intake have been studied, and have a
low prevalence of hypertension,10 although long-term effects of low in-
take on health have not been evaluated as mean life expectancy in
these population was short (40 years). There is a positive association
between increasing sodium intake and blood pressure, in observational
and experimental research studies, with inter-individual variability.
Reductions in sodium also appear to affect cardiovascular dynamics,
with animal models demonstrating low sodium intake associated with
attenuated pressor responses during stress (e.g. septic shock).11,12 Our
understanding of the physiology of sodium intake, storage and excre-
tion is continuing to evolve. For example, recent evidence suggests that
sodium excretion demonstrates cyclic variations, and the majority of
sodium is stored in skin, subcutaneous lymphatic networks and in
muscle, and partly regulated by the immune system.13,14 These obser-
vations raise issues related to measurement of sodium and need to
gain better understanding of potential effects of manipulating sodium
intake on the immune system. A recent study also suggests that sodium
that is still well within the ‘normal’ range may be more hazardous than
previously thought in hospitalized subjects.15
Measurement of salt intake
Individual level assessment of sodium
consumption
A prerequisite for effective programmes to modify risk factors, is an abil-
ity to accurately measure the exposure using simple methods (e.g.
blood pressure, cholesterol, smoking). A key obstacle to making quanti-
tative individual-level recommendations on sodium intake targets, is the
lack of valid and reliable methods to objectively quantify sodium intake
in individuals. At present, there is no routine approach to accurately
measuring sodium intake in individuals. Accurate objective
Sodium intake and CVD in LMIC 713
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measurement requires multiple 24-h urine collections, which is imprac-
tical in clinical practice.16 Therefore, while guidelines may recommend
an intake of sodium < 2.3 g/day, this target is relatively meaningless to
both clinician and patient, as it is not supported by an available objective
measurement. In contrast, recommendations on blood pressure targets
are based on simple measurements, which are suitable for both screen-
ing and monitoring change over time, which are readily interpreted and
implemented by clinician and patient, and can be applied in all settings
given the ease of blood pressure measurement. In contrast to other
dietary recommendations (e.g. increased consumption of fruits and
vegetables) where intake is directly observable, self-assessment of so-
dium intake range is poor, which may be related to the fact that much
of sodium intake is hidden (embedded within foods, particularly in
high-income countries), and the accuracy of self-predicted sodium in-
take appears to be independent of knowledge and attitudes to sodium
intake.17 Even subjective categorization of individuals into high, medium
and low sodium intake is poor, although dietary questionnaires are gen-
erally good at identifying groups and individuals who consume high so-
dium, but these require validated questionnaires to specific populations
as different populations have distinct dietary patterns. Moreover, stand-
ard food composition tables developed in one setting may not apply to
others, where the same descriptors may include differently constituted
foodstuffs.18 The implication, therefore, is that a policy targeting individ-
ual consumption should incorporate recommendations for individuals,
which are not dependent on numeric targets, but based on practical as-
sessment of diet to identify high sodium foods and those consuming
high sodium diets. In such individuals, reduction of sodium intake can, in
theory, be facilitated by recommendations to avoid/reduce sodium in
food preparation and at the table, and avoid (or replace) specific foods
that are high in sodium, rather than targeting a specific quantitative tar-
get for sodium intake. However, such an approach requires a detailed
knowledge of food items with a high sodium content, taking account of
the dietary variations that exist not only between countries but also
among different regions of a country. Even with common foods, such
as breads, sodium content can vary widely, but there are also many
foodstuffs that are common in some settings but rare in others (e.g.
salted fish such as bacalhau and its variants). Examples of dietary
screening tools exist, but very few have been validated in LMICs.
Population-level assessment of sodium
consumption
Employing multiple 24-h urinary collections is considered to be the ref-
erence standard for measuring sodium intake in populations, but chal-
lenging to complete in large population studies . Recent research has
suggested that use of spot urine, or particularly fasting urine samples,
which employ a formula-derived approach, appears suitable to estimate
mean intakes at a population-level or subdivide large populations into
those who, on average, have high, moderate and low sodium intakes.19
Spot or fasting urine measurement offers the potential to achieve more
representative samples in a population (external validity), since use of
24-h collections are burdensome and associated with a high rate of
non-adherence for complete collections. This creates an inherent risk
of selection bias (i.e. individuals who are adherent with 24-h collections
differ from those who are not). Intraclass correlation (ICC) for single
urine-formula derived estimates of 24-h urinary sodium excretion are
good (0.71 in largest validation study of fasting urine) and comparable
to the ICC for single office blood pressure measure compared to 24-h
ambulatory blood pressure measurements. However, while there is ac-
ceptance that blood pressure measured during office visits is suitable
for large epidemiologic studies, there is debate about whether spot or
fasting urines are appropriate in large epidemiologic studies to estimate
mean intake or report on association with clinical outcomes. WHO
does consider spot/fasting urine assessment in populations to be appro-
priate for measuring mean sodium intake. Dietary questionnaires, using
either food frequency questionnaire or 24-h dietary recall, are more
convenient but more time-consuming to complete than single urine
measures. Dietary questionnaires require validation in population with
distinct dietary patterns and different sources of sodium intake.
Generally dietary assessments provide a lower, and less reliable, quanti-
fication of sodium intake, compared to urinary measurements, which
presents special challenges for between-study comparisons. A main ad-
vantage of dietary assessment is the identification of food items that are
high in sodium, and measurement of overall dietary quality to guide
other types of dietary recommendations.
Regional variations in sodium
intake
Globally, the mean intake of sodium is estimated at 3.95 g/day by the
Global Burden of Disease (GBD) collaboration, in a meta-analysis of
surveys from 187 countries, using 24-h urine collections.20 Intakes
were highest in East Asia, Central Asia and Eastern Europe (mean
>4.2 g/day) and in Central Europe and Middle East/North Africa
(3.9–4.2 g/day). Mean intakes in North America, Western Europe,
and Australia/New Zealand ranged from 3.4 to 3.8 g/day. Intakes
were lower (< 3.3 g/day), but more uncertain, in sub-Saharan Africa
and Latin America. Between 1990 and 2010, there was a suggestion
of slight increases in overall sodium intakes. These regional variations
are consistent with reports from the PURE study involving 18 coun-
tries which used 24-h formula-derived estimates from fasting morning
urine specimens, which was published after this systematic review.21
In addition to regional variations in mean sodium intake, there are
important variations in the degree to which intake is from discretionary
and non-discretionary sodium, which has implications for developing
approaches to reduce sodium intake, especially whether priority should
be given to a population vs. individual-level interventional approach.
The proportion of sodium intake from discretionary sources in North
America and Europe is about 10–25%, compared to about 70% in
China, other parts of Asia and Africa. Therefore, in countries with high
non-discretionary use, reducing sodium in processed or pre-packaged
foods through reformulation is more important, whereas in countries
with high discretionary use, reducing salt during cooking and added at
table appear to be the most relevant priority targets. Thus, knowledge
of the main sources of high sodium intake is a mandatory step in de-
veloping country-specific approaches to reducing high sodium intake.
Socioeconomic variation in
sodium intake
Studies in several countries have found that those with lower levels
of education or living in disadvantaged areas have higher salt intakes,
714 G. Mancia et al.
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and exhibit less change during the course of national salt reduction
campaigns.22,23
Effect of reducing sodium intake
on blood pressure
Evidence of an association between sodium intake and blood pres-
sure comes from numerous lines of evidence, including observational
research and results of clinical trials reporting a reduction in blood
pressure following lowering of sodium intake. In these studies, there
is evidence of variations in the associations among different sub-
groups of people, with a stronger association in older age groups,
people with hypertension and those consuming low potassium diets.
Clinical trials
Over 40 clinical trials have evaluated the effects of reducing sodium
intake on blood pressure, and other biomarkers. Of these, most
(> 95%) were short-term trials (< 6 months).24,25
Of short-term trials, the findings from the DASH trial have exerted
greatest influence on current guidelines, and demonstrated short-
term reductions in blood pressure (30 days) with reductions of so-
dium intake to under 1.5 g/day.26 In the DASH trial, all foods were
provided to participants, and was therefore conducted in a highly
controlled environment which cannot be replicated in routine daily
life. Such low intake levels have not been achieved after routine clin-
ician recommendations, or even with intensive counselling interven-
tions in RCTs. Whereas the short-term nature of the clinical
intervention is known, the long-term effect of this diet on blood pres-
sure and outcomes has not been established in RCTs.
The TOHP-II trial is the largest clinical trial (n= 2382) evaluating
the effectiveness of a counselling/educational intervention to reduce
sodium reduction and thus blood pressure, with a mean duration of
follow-up of 36 months.27 The trial was a 22 factorial that also eval-
uated a behavioural change intervention for weight loss. At 18
months, a mean sodium of 3.1 g/day (3.2 g/day at 36 months) was
achieved in the intervention group (vs.) compared to mean intake of
3.9 g/day (4.0 g/day at 36 months) in the control group. The differ-
ence in systolic blood pressure between sodium intake groups was
2.9 mmHg at 6 months, 2.0 mmHg at 18 months, and 1.2 mmHg at 36
months, with a reduction in the incidence of hypertension which also
diminished over time, with a risk ratio of 0.61 (P= 0.04) at 6 months,
0.88 (P= 0.28) at 18 months, and 0.82 (P= 0.05) at study end.28 This
trial suggests that a 0.8 g/day difference in sodium intake lowered
blood pressure by 2 mm Hg. While this may have been the case, re-
petitive urine collections were variable in TOPH II, imprecisely docu-
mented, and the goal in TOPH II was not to provide a long-term
study of cardiovascular events as the outcome. Finally, the circasep-
tan (7 day) variability in daily sodium excretion was unknown at the
time of TOPH II.12
The TONE trial evaluated a similar intervention to TOHP-II in
older adults (60–80 years) with controlled hypertension (n= 975).
Ninety days after introduction of the intervention, systolic blood
pressure was reduced by 3.4 mmHg. Withdrawal of antihypertensive
therapy began at 90 days, and the proportion of patients requiring
antihypertensive therapy was lower in the sodium intervention group
compared to control (24% vs. 38%).29 These data suggest that
despite sustained maintenance of most of the difference in sodium in-
take between intervention and control, the differences in blood pres-
sure were attenuated over time, and large trials with extended
duration of follow-up are needed to assess the long-term antihyper-
tensive effect of sodium reduction in this sodium intake range. In each
of these clinical trials, the control group did not include a control
intervention (e.g. dietary counselling that did not include advice on
salt intake), which means that they were unable to determine the ef-
fects of sodium reduction, independent of other dietary changes (e.g.
increase in fruit/vegetable intake). An educational intervention target-
ing school children in a cluster RCT in China (28 schools, 832 family
members) reported a reduction in sodium intake (0.8 g/day in adults
with mean intake of sodium 4.7 g/day), and, while blood pressure
increased in both the intervention and control groups during follow-
up, the increase was significantly less in the intervention group.30
There have been several meta-analyses of clinical trials evaluating
sodium reduction for blood pressure reduction.31,32 In a recent
meta-analysis of 34 blood pressure clinical trials (n= 3230), a reduc-
tion in sodium intake (1.76 g/day difference in mean change between
intervention and control) was associated with a mean 4.2/2.1 mmHg
reduction in blood pressure. Among participants with hypertension,
the blood pressure reduction was greater (-4.06/2.26 mmHg) com-
pared to those without hypertension (-1.38/0.58 mmHg).19 Duration
of follow-up may be an important determinant of treatment effect,
which was explored in another meta-analysis of blood pressure trials
that included 36 trials.24,25 In trials of < 3 months, 3–6 months and
more than 6 month’s duration, blood pressure reductions were 4.07/
1.67 mmHg, 1.91/1.33 mmHg and 0.88 mmHg/0.45 mmHg, respect-
ively. These data demonstrate the challenges faced by counselling
interventions in maintaining adherence to reduced sodium intake
from moderate to low intake levels over time, even when dietary
counselling is relatively intense, and raise a suspicion that the blood
pressure lowering effects of moderate sodium reduction may dimin-
ish over time, based on findings from the largest long-term trial
included in the review (TOHP trial).
A number of clinical trials have evaluated use of salt substitutes
(low-sodium salt) usually involving a reduction of the proportion of
NaCl proportion in total salt to about 45–65%, and replacing it with
KCl or MgSO2. This is especially applicable in populations with high
discretionary salt use (e.g. China). A meta-analysis of these clinical tri-
als (5 clinical trials, n= 1974) reported a reduction in blood pressure
(-4.9/1.5 mmHg) with use of salt substitutes, ranging from 6 months
to 2 years. A recent large cluster RCT in China (China Rural Health
Initiative-Sodium Reduction Study) randomized 120 villages to either
intervention (health education and access to salt substitution, with 30
of the 60 intervention villages also receiving a price subsidy as salt
substitute is more expensive than regular salt) or control.33 Among
1295 participants in the intervention villages (1063 with urine assess-
ment), there was a 0.3 g lower sodium intake (P= 0.03) on follow-up
compared to control (1272 participants, 1001 with urine assess-
ments). There was no significant difference in change in blood pres-
sure (-1.0/0.8 mmHg, P= 0.39 and 0.34, respectively). A large cluster
RCT of 600 villages with over 21 000 participants is being undertaken
in China designed to evaluate the effects of salt substitution on stroke
risk in individuals at high risk of stroke, over 5-year’s follow-up (SSaSS
trial). Findings from the SSaSS trial may have important implications
for population-level approach to prevention of stroke in
Sodium intake and CVD in LMIC 715
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communities with high discretionary sodium intake. However, as this
trial evaluated salt substitution in a region with high sodium intake, it
will be unable to determine the effect of lowering sodium intake
from moderate to low intake levels, and unable to determine the in-
dependent effect of sodium reduction from increased potassium in-
take on stroke risk.
Effects of sodium intake on
cardiovascular biomarkers
The level of sodium intake affects the renin-angiotensin-aldosterone
system (RAAS), with low sodium intake resulting in activation in
RAAS shown in short-term studies.34,35 Activation of the sympathetic
nervous system with an impairment of reflex homeostatic control
has been reported.28,24 However, the clinical relevance of this obser-
vation is uncertain, since some effective antihypertensive therapies
that lower blood pressure and CVD also increase renin levels and
sympathetic nerve activity levels, and it is unclear whether these ef-
fects persist during long-term low-sodium intake. It does however
demonstrate that sodium intake exerts endocrine feedback effects at
sodium intakes below 3 g/day. Sodium intake also appears to exact ef-
fects on immune and inflammatory biomarkers, whose relevance re-
mains unclear. Moreover, in prospective cohort studies, the
magnitude of association between sodium intake and cardiovascular
outcomes is only modestly attenuated after adjustment for blood
pressure, suggesting that the potential adverse effects on cardiovas-
cular outcome are only partly attributable to changes in blood pres-
sure. These data suggest that the effects of changes in sodium intake
on health are complex, and could be mediated through a number of
different physiologic mechanisms, including, but not isolated to, blood
pressure.
Effect of reducing sodium intake
on cardiovascular disease
Clinical trials
No RCTs have been undertaken to determine specifically whether
low compared to moderate sodium intake reduces the incidence of
CV events or death (compared to moderate intake). Meta-analyses
of those blood pressure trials that reported CV events do not report
a significant reduction in CVD with lowering sodium intake, but these
trials are underpowered to detect moderate risk reductions. An ex-
tended observational follow-up of the TOHP I and II trials reported
on the risk of death and CV events (composite of myocardial infarc-
tion, stroke, coronary revascularization or cardiovascular death) dur-
ing 10–15 years after completion of the trials, which reported a
reduction (OR 0.75; 99% CI 0.59–0.99) on adjusted analyses, but not
in unadjusted analyses. However, there were very high rates of loss
to follow-up for CV outcomes, as this was opportunistic rather than
planned extended observation follow-up. For all-cause mortality
(100% follow-up), there was complete determination of outcome,
and no significant association. In summary, no individual trial, or com-
bination of all longer-term trials, is sufficiently powered to detect
whether moderate risk reduction in CVD associated with reducing
sodium intake. While there are also no large RCTs demonstrating a
reduction in CVD with reducing high sodium intake (>5 g/day), the
consistency of findings from blood pressure trials and observational
studies provide evidence that reducing high sodium intake will reduce
blood pressure and CVD, in the absence of harm, especially in people
with hypertension.
A small cluster RCT (n= 1981) conducted in five kitchens of vet-
eran’s retirement homes in Taiwan, in which participants increased
potassium consumption and reduced sodium consumption through
use of potassium-enriched salt, found a reduction in cardiovascular
mortality (HR 0.59; 95% CI 0.37–0.95) in those assigned to the higher
potassium group.25 The trial, which utilized cluster randomization,
was analysed using individual-level (inappropriately), rather than
cluster-level data. Moreover, in that trial, sodium intake was esti-
mated to be reduced from 5.2 g/day to 3.8 g/day, with a proportion-
ately larger effect on potassium intake than sodium intake. Thus, it is
necessary to await the findings of the SSaSS trial to ascertain the ef-
fectiveness of sodium reduction through salt substitution interven-
tion in the setting of high levels of discretionary salt use.
Prospective cohort studies
Among individual studies which have included a defined group with
high sodium intake (>5g/day), most report an overall increased risk
of CV events in these groups.36 However, in many prospective co-
hort studies, urinary samples were collected for a variety of purposes,
and not specifically to measure sodium intake. Meta-analyses of pro-
spective cohort studies have generally compared the lowest quintile
of sodium intake with highest quintiles.37 In the most recent of these
meta-analyses, there was a significant association between highest so-
dium intake quintile and stroke (RR 1.24; 95% CI 1.08–1.43) and fatal
coronary events (RR 1.32; 1.13–1.53), but not all-cause mortality (RR
1.06; 0.94–1.20) or all CVD mortality (1.12; 0.93–1.34). In another
meta-analysis38 that compared high (>5 g/day) sodium intake to mod-
erate (2.7–5 g/day) sodium intake, there was an increased risk of all-
cause mortality (HR 1.16; 1.03–1.30), CVD (HR 1.12; 1.02–1.24),
stroke (HR 1.18; 1.05–1.33), and heart disease (HR 1.17; 1.08–1.27).
In that meta-analysis,39 a comparison of low sodium intake (< 2.7 g/
day) with moderate/usual intake (2.7–5 g/day) intake found that mod-
erate sodium intake was associated with a lower risk of all-cause
mortality (0.91; 0.82–0.99) and all CVD mortality (HR 0.90; 0.82–
0.99), compared to low intake (< 2.7 g/day). Following these meta-
analyses, the PURE study, the largest international study (n= 101 945,
3.7 years follow-up) to evaluate the association between sodium in-
take (based on formula-derived 24-h sodium excretion from a fasting
urine sample) reported a J-shaped association between sodium ex-
cretion and CVD incidence and mortality, consistent with findings
from the most recent meta-analysis.40 In contrast to the earlier stud-
ies that were included in the meta-analysis, the PURE study had
greater representation from LMICs and so are probably most rele-
vant to informing policy in LMICs. One study, which analysed an ex-
tended follow-up of the control group (n= 2275) in the TOHP trial,
reported a linear association between sodium intake and CVD, but
the proportion of the population with low sodium intake was small
(n= 235) with wide confidence intervals in the lower intake range.41
Observational studies, even when conducted with methodological
rigour and analysed to optimally adjust for measured confounders,
have inherent limitations, including residual confounding and reverse
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causation.42 In the CRIC cohort, repeated 24-h urine collections
were used to estimate sodium excretion wherein sodium was
strongly related to CVD events, for sodium intakes over 4.5 g/day.43
In another meta-analysis of observational studies that employed the
Kawasaki formula and created two groups based on presence or ab-
sence of hypertension, a direct relationship between sodium excre-
tion and CVD was noted in the hypertensive group for high vs.
moderate sodium excretion but an inverse relationship was noted
for both the hypertensive and normotensive groups.9 While the to-
tality of evidence from observational studies raise caution about the
safety of reducing sodium intake to very low levels, and none report
a significantly lower risk of CVD for low vs. moderate sodium intake,
definitive evidence can only come from large RCTs.
There are no prospective RCTs with hard major adverse cardiac
events (MACE) cardiovascular endpoints. TOPH II and TONE were
never conceived as such. Admittedly, an individual-level RCT with so-
dium reduction as the only variable would be exceedingly difficult in
free-living individuals for reasons made clear above.
What factors modify the
association between sodium
intake and CVD?
Hypertension
Clinical trials and observational studies have generally reported a
greater blood pressure lowering effect of sodium reduction among
individuals with hypertension. Two prospective cohort studies have
reported an effect-modification of hypertension for CVD. In the
PREVEND study, (n= 7543),44 an association between high sodium
intake and CVD was confined to participants with baseline hyperten-
sion. In the PURE cohort,45 a significant interaction between baseline
hypertension and sodium intake (P= 0.02) was found, with the
increased risk of CVD associated with high sodium intake only found
in those with hypertension. However, the increased risk of CVD and
mortality at sodium intake below 3 g/day was seen in those with and
without hypertension.
Diabetes mellitus
There is no convincing evidence that the presence of diabetes melli-
tus modifies the association between sodium intake and clinical out-
comes, although reports of an increased CV risk with low sodium
intake have been prominent in patients with diabetes.
Obesity
Two studies reported an increased risk of higher sodium intake among
participants with increased BMI (but not in the entire cohort).39,46
Other dietary factors
Many dietary factors (e.g. fruit, vegetable and meat intake) and dietary
patterns (e.g. prudent diet, Mediterranean diet) have been associated
with differing risk of CVD.45,47
Overall diet quality appears to be an important modifying effect,
supported by evidence from the DASH-Sodium trial, which reported
a greater blood pressure lowering effect among those with a healthy
CV diet, compared to a less healthy one.
In this regards, potassium intake may modify the association be-
tween sodium intake, blood pressure and CVD.48 Epidemiological
studies have also reported that increased potassium intake is associated
with reduced risk of CVD, particularly for stroke.49,50 While the effect
of dietary sodium is likely to be the same regardless of source, certain
sources may provide other nutrients and micro-nutrients with conse-
quences for CVD, creating potential for confounding. For example, in
some regions, high sodium intake may be primarily from processed
foods and food types such as fried foods, especially in high-moderate
income countries. In other regions, the main sources of high sodium in-
take may include salted fish and vegetables, which, independently, do
not increase CV risk.
Cardiovascular disease
The blood pressure lowering effects of reducing sodium intake appear
similar in populations with and without CVD, although most studies
have been in populations without CVD. The relative association be-
tween sodium intake and CVD also appears to be similar, although
rates of events are higher in populations with prior CVD.51,52 Patients
with heart failure represent a unique population, where the effects of
low sodium intake require further study (and are dealt with in another
section). The PREVEND study reported pro-BNP to be an effect-
modifier of the association between sodium intake and CVD.
Genetic determinants of salt sensitivity
Some individuals are more sensitive to the hypertensive effects of
increased sodium intake, termed ‘salt sensitivity’.53 About 30–50% of
persons with hypertension are thought to be salt-sensitive. An inten-
sive area of research seeks to identify genetic polymorphisms that
are associated with both hypertension and ‘salt sensitivity’.54 The clin-
ical relevance of salt sensitivity is uncertain, as definition and identifi-
cation of salt sensitive populations lack clarity, although people who
develop hypertension appear to have a greater increase in blood
pressure for a given increase in sodium intake compared to those
who do not develop hypertension.
National interventions to reduce
sodium intake
A recent systematic review examined 39 state and community level
interventions, which included nutrition education programmes, pub-
lic education campaigns, changes to the food environment, other
‘novel’ approaches and multifaceted approaches.55 It concluded that
there was some evidence of effectiveness but most studies had meth-
odological limitations and more robust evaluations were needed.
The WHO has published guidelines on approaches to develop, im-
plement, and monitor sodium intake, and integrate them with
approaches to eliminate iodine deficiency. However, such programs
have been adopted or implemented56 mainly in higher income coun-
ties. Interventions can be divided into those seeking to change individ-
ual choices, such as consumer education and front of pack labelling,
and those limiting the choices that are available, such as reformulation
or changes to cooking methods in institutional settings (e.g. schools,
workplaces). The latter can be further divided into those that are vol-
untary and those that are imposed through legislation.
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In some of these countries, reductions in mean sodium intake have
been reported, which was most apparent in countries with a rela-
tively higher mean intake of sodium (>4 g/day), but less evidence is
available in countries with mean intake in the moderate range.57
However, a separate meta-analysis completed by the GBD did not
report reductions in sodium intake in any region from 1990 to 2010.
In most regions of Africa and Asia (with exception of China), no pub-
lic health strategy has been developed to reduce sodium intake. In
China, where mean intake of sodium is high (4.8 g/day), there is evi-
dence of a reduction in mean sodium intake over time (from 6.7 g/
day to 4.8 g/day from 1991 to 2009), which has been largely due to
reduction in discretionary salt intake. However, the reduction in dis-
cretionary intake has been countered by a recent increase in con-
sumption of processed foods and non-discretionary salt intake. This
is not unique to China and reflects the increasing globalization of the
food industry. This has led to pressure for reformulation to reduce
sodium content which can, as noted above, be voluntary or imposed
through legislation or regulation. Unsurprisingly, the food industry
argues for voluntary agreements and for a major role in developing
standards, although even in high-income countries progress has been
mixed unless there is a credible threat of regulation.58,59 There is
now extensive evidence from other areas of public health that volun-
tary approaches more generally are often ineffective, with industry
emphasizing measures that impose least costs on it rather than those
that work, and committing to measures that it is already
implementing.60,61
Consequently, some countries have implemented legislative inter-
vention to reduce sodium intake, including mandatory salt targets
(e.g. Paraguay), taxation on high salt foods (e.g. Portugal), regulations
to ensure front of pack labelling (e.g. Ecuador, Indonesia) and stand-
ards for salt in procurement policies (e.g. Argentina, Latvia). Other
LMIC are developing approaches to inform strategies to reduce so-
dium intake.62
Summary and recommendations
Research to address knowledge gaps
Measuring sodium intake?
• There is a need to identify simple methods to objectively measure
sodium intake that are valid and reliable and applicable in diverse
populations. The absence of such measures is an obstacle to im-
plementing strategies to reduce sodium intake, and evaluating dif-
ferent sodium intake targets for cardiovascular prevention.
• There is a need to complete studies to identify key sources of
high sodium intake, discretionary and non-discretionary, in differ-
ent regions of the world with distinct dietary patterns, particularly
in LMICs. It is necessary to develop simple screening methods to
identify populations consuming high sodium intake, which can be
administered by healthcare workers and self-assessed.
Feasibility of long-term low sodium intake?
• Despite recommendations for population-wide low sodium intake,
it has not been shown that sustained low sodium intake is feasible
in free living individuals. Examples of reducing sodium intake from
high to moderate intake levels have been reported in countries
(e.g. Finland, Japan). We recommend studies to identify simple/
generalizable interventions to reduce sodium intake to low intake
levels, which would enable studies to assess the feasibility and ef-
fectiveness of such sodium intake targets in the long-term (e.g.
over 2 years).
• We note the particular paucity of studies of from LMIC in differ-
ent regions of the world (e.g. Africa, Latin America, India, or SE
Asia) and we recommend that such studies should be conducted
in each region given the marked variations in diet and cooking
methods in these regions. Such studies can also document
whether the reductions in sodium will also lead to similar reduc-
tions in blood pressure, in populations consuming different diets.
In addition, such studies should identify regional and local barriers
to sodium intake reduction.
Long-term low sodium intake reduce the risk of cardio-
vascular disease and death?
• We support the conduct of definitive RCTs, comparing low so-
dium intake (< 2.4 g/day) to moderate intake (2.4–5 g/day) on car-
diovascular events and mortality. Currently, there is insufficient
information to reliably answer this question, as there are compet-
ing lines of evidence from blood pressure trials (which report a re-
duction in blood pressure) and epidemiologic studies of
association between sodium intake and cardiovascular events
(some of which report a higher risk associated with low sodium
intake).
Practical recommendations based on
current evidence
A. Population-level
Measuring sodium intake (population)
• Measure sodium intake in the population (average intake and dis-
tribution), to determine current and future (monitoring) sodium
intake. Measuring and monitoring of sodium intake using formula-
derived estimates of 24-h sodium excretion from morning fasting
urines are reasonable, and ensure standardized measurement in
different regions. Employ dietary assessments to determine key
sources of sodium intake.
Sodium intake target (population)
• Sodium is an essential nutrient, and is a dietary requirement for all
humans, and should be included in a healthy balanced diet. Excess
sodium intake is an important determinant of hypertension and
CV risk.
• For population-wide recommendation of sodium intake, lowering
sodium intake from high intakes (> 5 g/day) to moderate intakes
(3–5 g/day) is associated with lower blood pressure and lower
CVD in observational studies. Although there are no RCTs dem-
onstrating a reduction in CVD with lowering sodium intake from
high to moderate levels, the consistency in data from observa-
tional studies (reporting a lower CV risk in populations consuming
moderate intake compared to high sodium intake) and clinical tri-
als (reporting a reduction in blood pressure) support reducing
high sodium intake in all populations.
 In populations with high mean sodium intake (e.g. China), a
population-wide approach to sodium reduction is probably appro-
priate, with a target of reducing mean sodium intake by 30%
(WHO).
 In countries/populations where mean intake is moderate (e.g.
3–5 g/day, a targeted approach of reducing salt in those consum-
ing high salt intake is appropriate, especially among those with
hypertension.
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.• Reducing mean sodium intake from moderate intake to below 3
g/day is expected to reduce blood pressure, but the effects on
CVD and mortality are uncertain, especially in populations who
do not have hypertension.
• Recommendations on diet should be included within an overall rec-
ommendation for healthy dietary pattern, rich in fruit and vegetables
(e.g. Mediterranean diet) and other lifestyle recommendations.
Reducing sodium intake (intervention in populations)
• Existing interventions to reduce high sodium intake in populations
appear reasonable, including educational interventions in public in-
stitution settings (e.g. School Edu-Salt), food reformulation, con-
sumer education, front of pack labelling, and intervention in public
institution settings. Such interventions are expected to reduce so-
dium intake from high to moderate intake ranges, based on prior
ecological research studies, and community-level education inter-
vention trials. Educational interventions should target overall diet-
ary pattern but are not a substitute for population level measures.
Educational interventions should be informed by research studies
of local dietary patterns, and dietary sources of high sodium.
• Current evidence supports the safety of low-sodium salt substi-
tutes, although a large ongoing clinical trial to determine its effect-
iveness in reducing stroke risk is pending (SSaSS Trial).
B Individual-level
Measuring sodium intake (individual)
• Practical measurement of sodium intake requires dietary assess-
ment, as there is no practical objective measurement of sodium
intake.
• Screening of individuals, especially those with hypertension, for
high sodium intake factors (e.g. adding salt in cooking, adding salt
in table, excess consumption of processes foods high in salt con-
tent) is a practical approach to identifying individuals consuming
high sodium diets.
Sodium intake target (individual)
• Sodium is an essential nutrient, and is a dietary requirement for all
humans, and should be included in a healthy balanced diet. Excess
sodium intake is an important determinant of hypertension and
CV risk.
• As there is no practical method to objectively and accurately
measure sodium intake in individuals, we recommend avoiding a
numeric target in individual counselling. Rather, individuals should
be screened for their consumption of food patterns. Food items
known to be associated with high sodium content should be
reduced, or substituted, and reductions/substitutions recom-
mended. Such an approach requires knowledge of main sources
of high sodium intake (discretionary vs. non-discretionary) and
high sodium food items that are consumed commonly in the set-
ting in question.
Reducing sodium intake target (intervention in individuals)
• Individual-level counselling/educational interventions that have
been shown to reduce sodium intake in clinical trials are impracti-
cal for primary care settings, although these have targeted reduc-
ing sodium intake from moderate to low sodium intake levels.
• Family and community-level interventions have been shown to re-
duce high sodium intake, although the available evidence suffers
from methodological limitations.
• Current evidence supports the safety of low-sodium salt substi-
tutes, although a large ongoing clinical trial to determine its effect-
iveness in reducing stroke risk is pending (SSaSS Trial).
Conflict of interest: none declared.
References
1. Bonita R, Magnusson R, Bovet P, Zhao D, Malta DC, Geneau R, Suh I,
Thankappan KR, McKee M, Hospedales J, de Court M, Capewell S, Beaglehole R.
Country actions to meet UN commitments on non-communicable diseases: a
stepwise approach. Lancet 2013;381:575–584.
2. https://sustainabledevelopment.un.org/sdg3.
3. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional
burden of disease and risk factors, 2001: systematic analysis of population health
data. Lancet 2006;367:1747–1757.
4. He J, Whelton PK. Salt intake, hypertension and risk of cardiovascular disease: an
important public health challenge. Int J Epidemiol 2002;31:327–331.
5. 2013 Practice guidelines for the management of arterial hypertension of the
European Society of Hypertension (ESH) and the European Society of
Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial
Hypertension. J Hypertens 2013;31:1925–1938.
6. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston MN, Hubbard VS, Lee IM,
Lichtenstein AH, Loria CM, Millen BE, Nonas CA, Sacks FM, Smith SC Jr, Svetkey
LP, Wadden TA, Yanovski SZ. 2013 AHA/ACC guideline on lifestyle manage-
ment to reduce cardiovascular risk: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines. J Am
Coll Cardiol 2014;63(25 Pt B):2960–2984.
7. Sixty-sixth World Health Assembly. Follow-upto the Political Declaration of
the High-level Meeting of the General Assembly on the Prevention and
Control of Non-communicable Diseases WHA 66.10. 2013 [cited 2014 21
August].
8. Whelton PK, Appel LJ, Sacco RL, Anderson CA, Antman EM, Campbell N,
Dunbar SB, Frohlich ED, Hall JE, Jessup M, Labarthe DR, MacGregor GA, Sacks
FM, Stamler J, Vafiadis DK, Van Horn LV. Sodium, blood pressure, and cardiovas-
cular disease: further evidence supporting the American Heart Association so-
dium reduction recommendations. Circulation 2012;126:2880–2889.
9. Mente A, O’donnell M, Rangarajan S, Dagenais G, Lear S, McQueen M, Diaz R,
Avezum A, Lopez-Jaramillo P, Lanas F, Li W, Lu Y, Yi S, Rensheng L, Iqbal R,
Mony P, Yusuf R, Yusoff K, Szuba A, Oguz A, Rosengren A, Bahonar A, Yusufali
A, Schutte AE, Chifamba J, Mann JF, Anand SS, Teo K, Yusuf S. Associations of
urinary sodium excretion with cardiovascular events in individuals with and with-
out hypertension: a pooled analysis of data from four studies. Lancet
2016;388:465–475.
10. Oliver WJ, Cohen EL, Neel JV. Blood pressure, sodium intake, and sodium
related hormones in the Yanomamo Indians, a no-salt culture. Circulation
1975;52:146–151.
11. Ely DL, Paradise NF, Folkow B. Blood pressure and neurogenic adaptations to
reduced dietary sodium in the SHR model of hypertension. Klin Wochenschr
1991;69 (Suppl 25):58–72.
12. Nilsson H, Ely D, Friberg P, Folkow B. Effects of low and high Na diets on cardio-
vascular dynamics in normotensive and hypertensive rats: neuroeffector charac-
teristics of the resistance vessels. J Hypertens Suppl 1984;2:S433–S435.
13. Wiig H, Schroder A, Neuhofer W, Jantsch J, Kopp C, Karlsen TV, Boschmann M,
Goss J, Bry M, Rakova N, Dahlmann A, Brenner S, Tenstad O, Nurmi H,
Mervaala E, Wagner H, Beck FX, Muller DN, Kerjaschki D, Luft FC, Harrison
DG, Alitalo K, Titze J. Immune cells control skin lymphatic electrolyte homeosta-
sis and blood pressure. J Clin Invest 2013;123:2803–2815.
14. Rakova N, Juttner K, Dahlmann A, Schroder A, Linz P, Kopp C, Rauh M, Goller
U, Beck L, Agureev A, Vassilieva G, Lenkova L, Johannes B, Wabel P, Moissl U,
Vienken J, Gerzer R, Eckardt KU, Muller DN, Kirsch K, Morukov B, Luft FC,
Titze J. Long-term space flight simulation reveals infradian rhythmicity in human
Na(þ) balance. Cell Metab 2013;17:125–131.
15. McKee M, Exall S, Stuckler D, Wolff A. 0Normal0 serum sodium concentration
among inpatients over 65 admitted to hospital: an observational study. Postgrad
Med J 2016;92:21–26.
16. Lerchl K, Rakova N, Dahlmann A, Rauh M, Goller U, Basner M, Dinges DF, Beck
L, Agureev A, Larina I, Baranov V, Morukov B, Eckardt KU, Vassilieva G, Wabel
P, Vienken J, Kirsch K, Johannes B, Krannich A, Luft FC, Titze J. Agreement be-
tween 24-hour salt ingestion and sodium excretion in a controlled environment.
Hypertension 2015;66:850–857.
17. Newson RS, Elmadfa I, Biro G, Cheng Y, Prakash V, Rust P, Barna M, Lion R,
Meijer GW, Neufingerl N, Szabolcs I, van ZR, Yang Y, Feunekes GI. Barriers for
progress in salt reduction in the general population. An international study.
Appetite 2013;71:22–31.
Sodium intake and CVD in LMIC 719
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/38/10/712/2932130 by Bernetta Evans user on 13 August 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
18. Vaask S, Pomerleau J, Pudule I, Grinberga D, Abaravicius A, Robertson A, McKee
M. Comparison of the micro-nutrica nutritional analysis program and the Russian
food composition database using data from the baltic nutrition surveys. Eur J Clin
Nutr 2004;58:573–579.
19. Huang L, Crino M, Wu JH, Woodward M, Barzi F, Land MA, McLean R, Webster
J, Enkhtungalag B, Neal B. Mean population salt intake estimated from 24-h urine
samples and spot urine samples: a systematic review and meta-analysis. Int J
Epidemiol 2016;45:239–250.
20. Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, Engell RE, Lim SS,
Danaei G, Mozaffarian D. Global, regional and national sodium intakes in 1990
and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary sur-
veys worldwide. BMJ Open 2013;3:e003733.
21. Mente A, O’donnell MJ, Rangarajan S, McQueen MJ, Poirier P, Wielgosz A,
Morrison H, Li W, Wang X, Di C, Mony P, Devanath A, Rosengren A, Oguz A,
Zatonska K, Yusufali AH, Lopez-Jaramillo P, Avezum A, Ismail N, Lanas F, Puoane
T, Diaz R, Kelishadi R, Iqbal R, Yusuf R, Chifamba J, Khatib R, Teo K, Yusuf S.
Association of urinary sodium and potassium excretion with blood pressure. N
Engl J Med 2014;371:601–611.
22. Keita AD, Casazza K, Thomas O, Fernandez JR. Neighborhood-level disadvantage
is associated with reduced dietary quality in children. J Am Diet Assoc
2009;109:1612–1616.
23. Ji C, Cappuccio FP. Socioeconomic inequality in salt intake in Britain 10 years
after a national salt reduction programme. BMJ Open 2014;4:e005683.
24. Grassi G, Dell’oro R, Seravalle G, Foglia G, Trevano FQ, Mancia G. Short- and
long-term neuroadrenergic effects of moderate dietary sodium restriction in es-
sential hypertension. Circulation 2002;106:1957–1961.
25. Chang HY, Hu YW, Yue CS, Wen YW, Yeh WT, Hsu LS, Tsai SY, Pan WH.
Effect of potassium-enriched salt on cardiovascular mortality and medical ex-
penses of elderly men. Am J Clin Nutr 2006;83:1289–1296.
26. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E,
Conlin PR, Miller ER III, Simons-Morton DG, Karanja N, Lin PH. Effects on blood
pressure of reduced dietary sodium and the Dietary Approaches to Stop
Hypertension (DASH) diet. DASH-sodium collaborative research group. N Engl J
Med 2001;344:3–10.
27. Effects of weight loss and sodium reduction intervention on blood pressure and
hypertension incidence in overweight people with high-normal blood pressure.
The trials of hypertension prevention, phase II. The trials of hypertension pre-
vention collaborative research group. Arch Intern Med 1997;157:657–667.
28. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Bolla G, Mancia G. Baroreflex
impairment by low sodium diet in mild or moderate essential hypertension.
Hypertension 1997;29:802–807.
29. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB,
Kumanyika S, Lacy CR, Johnson KC, Folmar S, Cutler JA. Sodium reduction and
weight loss in the treatment of hypertension in older persons: a randomized
controlled trial of nonpharmacologic interventions in the elderly (TONE).
TONE collaborative research group. JAMA 1998;279:839–846.
30. He FJ, Wu Y, Feng XX, Ma J, Ma Y, Wang H, Zhang J, Yuan J, Lin CP, Nowson C,
MacGregor GA. School based education programme to reduce salt intake in chil-
dren and their families (School-EduSalt): cluster randomised controlled trial. BMJ
2015;350:h770.
31. He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood
pressure: cochrane systematic review and meta-analysis of randomised trials.
BMJ 2013;346:f1325.
32. Aburto NJ, Ziolkovska A, Hooper L, Elliott P, Cappuccio FP, Meerpohl JJ. Effect
of lower sodium intake on health: systematic review and meta-analyses. BMJ
2013;346:f1326.
33. Li N, Yan LL, Niu W, Labarthe D, Feng X, Shi J, Zhang J, Zhang R, Zhang Y, Chu
H, Neiman A, Engelgau M, Elliott P, Wu Y, Neal B. A large-scale cluster random-
ized trial to determine the effects of community-based dietary sodium
reduction–the China rural health initiative sodium reduction study. Am Heart J
2013;166:815–822.
34. Graudal NA, Hubeck-Graudal T, Jurgens G. Effects of low sodium diet versus
high sodium diet on blood pressure, renin, aldosterone, catecholamines, choles-
terol, and triglyceride. Cochrane Database Syst Rev 2011;CD004022.
35. He FJ, Li J, Macgregor GA. Effect of longer-term modest salt reduction on blood
pressure. Cochrane Database Syst Rev 2013;4:CD004937.
36. Alderman MH, Cohen HW. Dietary sodium intake and cardiovascular mortality:
controversy resolved?. Curr Hypertens Rep 2012;14:193–201.
37. Strazzullo P, D’elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardio-
vascular disease: meta-analysis of prospective studies. BMJ 2009;339:b4567.
38. Graudal N, Jurgens G, Baslund B, Alderman MH. Compared with usual sodium
intake, low- and excessive-sodium diets are associated with increased mortality:
a meta-analysis. Am J Hypertens 2014;27:1129–1137.
39. He J, Ogden LG, Vupputuri S, Bazzano LA, Loria C, Whelton PK. Dietary sodium
intake and subsequent risk of cardiovascular disease in overweight adults. JAMA
1999;282:2027–2034.
40. O’donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, Yan H, Lee
SF, Mony P, Devanath A, Rosengren A, Lopez-Jaramillo P, Diaz R, Avezum A,
Lanas F, Yusoff K, Iqbal R, Ilow R, Mohammadifard N, Gulec S, Yusufali AH,
Kruger L, Yusuf R, Chifamba J, Kabali C, Dagenais G, Lear SA, Teo K, Yusuf S.
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N
Engl J Med 2014;371:612–623.
41. Cook NR, Appel LJ, Whelton PK. Lower levels of sodium intake and reduced
cardiovascular risk. Circulation 2014;129:981–989.
42. Cobb LK, Anderson CA, Elliott P, Hu FB, Liu K, Neaton JD, Whelton PK,
Woodward M, Appel LJ. Methodological issues in cohort studies that relate so-
dium intake to cardiovascular disease outcomes: a science advisory from the
American Heart Association. Circulation 2014;129:1173.
43. Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, Delafontaine P, Keane
MG, Mohler E, Ojo A, Rahman M, Ricardo AC, Soliman EZ, Steigerwalt S,
Townsend R, He J. Sodium excretion and the risk of cardiovascular disease in pa-
tients with chronic kidney disease. JAMA 2016;315:2200–2210.
44. Joosten MM, Gansevoort RT, Mukamal KJ, Lambers Heerspink HJ, Geleijnse JM,
Feskens EJ, Navis G, Bakker SJ; PREVEND Study Group. Sodium excretion and
risk of developing coronary heart disease. Circulation 2014;129:1121–1128.
45. Iqbal R, Anand S, Ounpuu S, Islam S, Zhang X, Rangarajan S, Chifamba J, Al-Hinai
A, Keltai M, Yusuf S. Dietary patterns and the risk of acute myocardial infarction in
52 countries: results of the INTERHEART study. Circulation 2008;118:1929–1937.
46. Klag MJ, He J, Coresh J, Whelton PK, Chen JY, Mo JP, Qian MC, Mo PS, He GQ.
The contribution of urinary cations to the blood pressure differences associated
with migration. Am J Epidemiol 1995;142:295–303.
47. Mente A, de KL, Shannon HS, Anand SS. A systematic review of the evidence
supporting a causal link between dietary factors and coronary heart disease. Arch
Intern Med 2009;169:659–669.
48. Morris RC Jr, Schmidlin O, Frassetto LA, Sebastian A. Relationship and interaction
between sodium and potassium. J Am Coll Nutr 2006;25(3 Suppl):262S–270S.
49. Khaw KT, Barrett-Connor E. Dietary potassium and stroke-associated mortality.
A 12-year prospective population study. N Engl J Med 1987;316:235–240.
50. Bazzano LA, He J, Ogden LG, Loria C, Vupputuri S, Myers L, Whelton PK.
Dietary potassium intake and risk of stroke in US men and women: National
health and nutrition examination survey I epidemiologic follow-up study. Stroke
2001;32:1473–1480.
51. Thomas MC, Moran J, Forsblom C, Harjutsalo V, Thorn L, Ahola A, Waden J,
Tolonen N, Saraheimo M, Gordin D, Groop PH. The association between diet-
ary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes.
Diabetes Care 2011;34:861–866.
52. Ekinci EI, Clarke S, Thomas MC, Moran JL, Cheong K, Macisaac RJ, Jerums G.
Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care
2011;34:703–709.
53. Felder RA, White MJ, Williams SM, Jose PA. Diagnostic tools for hypertension
and salt sensitivity testing. Curr Opin Nephrol Hypertens 2013;22:65–76.
54. Chu C, Wang Y, Ren KY, Yan DY, Guo TS, Zheng WL, Yuan ZY, Mu JJ. Genetic
variants in adiponectin and blood pressure responses to dietary sodium or po-
tassium interventions: a family-based association study. J Hum Hypertens
2016;30:563–570.
55. Christoforou A, Trieu K, Land MA, Bolam B, Webster J. State-level and
community-level salt reduction initiatives: a systematic review of global pro-
grammes and their impact. J Epidemiol Community Health 2016;70:1140–1150.
56. Trieu K, McLean R, Johnson C, Santos JA, Angell B, Arcand J, Raj TS, Campbell
NR, Wong MM, Leung AA, Neal B, Webster J. The science of salt: a regularly
updated systematic review of the implementation of salt reduction interventions
(June-October 2015). J Clin Hypertens (Greenwich) 2016;18:487–494.
57. Nowson C, Lim K, Grimes C, O’halloran S, Land MA, Webster J, Shaw J,
Chalmers J, Smith W, Flood V, Woodward M, Neal B. Dietary salt intake and dis-
cretionary salt use in two general population samples in Australia: 2011 and
2014. Nutrients 2015;7:10501–10512.
58. Monro D, Mhurchu CN, Jiang Y, Gorton D, Eyles H. Changes in the sodium
content of New Zealand processed foods: 2003-2013. Nutrients 2015;7:4054–4067.
59. He FJ, Brinsden HC, MacGregor GA. Salt reduction in the United
Kingdom: a successful experiment in public health. J Hum Hypertens 2014;28:
345–352.
60. Knai C, Petticrew M, Durand MA, Scott C, James L, Mehrotra A, Eastmure E, Mays
N. The public health responsibility deal: has a public-private partnership brought
about action on alcohol reduction?. Addiction 2015;110:1217–1225.
61. Magnusson R, Reeve B. Food reformulation, responsive regulation, and "regula-
tory scaffolding": strengthening performance of salt reduction programs in
Australia and the United Kingdom. Nutrients 2015;7:5281–5308.
62. Johnson C, Mohan S, Praveen D, Woodward M, Maulik PK, Shivashankar R,
Amarchand R, Webster J, Dunford E, Thout SR, MacGregor G, He F, Reddy KS,
Krishnan A, Prabhakaran D, Neal B. Protocol for developing the evidence
base for a national salt reduction programme for India. BMJ Open
2014;4:e006629.
719a G. Mancia et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/38/10/712/2932130 by Bernetta Evans user on 13 August 2019
